Published in Antimicrob Agents Chemother on June 01, 2002
TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell (2004) 2.61
Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell (2007) 2.25
Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother (2004) 1.98
Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob Agents Chemother (2004) 1.76
Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob Agents Chemother (2005) 1.76
Antifungal resistance and new strategies to control fungal infections. Int J Microbiol (2011) 1.44
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. Antimicrob Agents Chemother (2010) 1.39
Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob Agents Chemother (2004) 1.37
Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol (2003) 1.35
Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol (2002) 1.30
Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. Eukaryot Cell (2011) 1.07
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains. Antimicrob Agents Chemother (2008) 1.06
Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother (2003) 0.98
Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression. Antimicrob Agents Chemother (2005) 0.85
Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae. Antimicrob Agents Chemother (2015) 0.84
Comparative analysis of calcineurin signaling between Candida dubliniensis and Candida albicans. Commun Integr Biol (2012) 0.83
2-Amino-nonyl-6-methoxyl-tetralin muriate inhibits sterol C-14 reductase in the ergosterol biosynthetic pathway. Acta Pharmacol Sin (2009) 0.81
Evaluation of the new Micronaut-Candida system compared to the API ID32C method for yeast identification. J Clin Microbiol (2008) 0.80
Detection of species diversity in oral candida colonization and anti-fungal susceptibility among non-oral habit adult diabetic patients. J Nat Sci Biol Med (2014) 0.76
Transcriptomics Analysis of Candida albicans Treated with Huanglian Jiedu Decoction Using RNA-seq. Evid Based Complement Alternat Med (2016) 0.75
Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis. Front Microbiol (2017) 0.75
Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection. J Clin Microbiol (2004) 0.75
Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum. Mycopathologia (2017) 0.75
In vitro inhibitory activities of magnolol against Candida spp. Drug Des Devel Ther (2017) 0.75
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev (1998) 9.76
Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology (1995) 8.08
Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother (1995) 7.44
Computer-assisted methods for assessing strain relatedness in Candida albicans by fingerprinting with the moderately repetitive sequence Ca3. J Clin Microbiol (1990) 6.57
Current and emerging azole antifungal agents. Clin Microbiol Rev (1999) 5.70
Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother (1998) 4.93
Candida dubliniensis: characteristics and identification. J Clin Microbiol (1998) 4.23
Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2001) 4.05
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother (1997) 3.78
Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J Clin Microbiol (1997) 3.54
Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS (1997) 3.32
Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (1999) 3.19
Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis (1999) 2.96
Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother (1998) 2.93
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol (1998) 2.48
Candida dubliniensis fungemia: the first four cases in North America. Emerg Infect Dis (2000) 2.34
Prevalence of Candida dubliniensis isolates in a yeast stock collection. J Clin Microbiol (1998) 2.31
Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol (1996) 2.28
Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Nucleic Acids Res (1989) 2.27
Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea. J Clin Microbiol (1999) 2.15
Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett (1997) 2.15
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol (1999) 2.10
Candida dubliniensis: an emerging opportunistic pathogen. Curr Top Med Mycol (1997) 2.07
Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother (1998) 2.03
Identification of Candida dubliniensis in a prospective study of patients in the United States. J Clin Microbiol (1999) 2.02
Molecular and phenotypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patients. Oral Dis (1997) 1.87
Candida dubliniensis: phylogeny and putative virulence factors. Microbiology (1998) 1.76
Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis (1998) 1.66
A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem (2000) 1.62
Development and characterization of complex DNA fingerprinting probes for the infectious yeast Candida dubliniensis. J Clin Microbiol (1999) 1.56
Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol (1998) 1.55
Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis (1999) 1.51
Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Israel. J Clin Microbiol (2000) 1.49
Modeling cytochrome P450 14 alpha demethylase (Candida albicans) from P450cam. J Mol Graph (1994) 1.37
Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1999) 1.30
Development of simultaneous resistance to fluconazole in Candida albicans and Candida dubliniensis in a patient with AIDS. J Antimicrob Chemother (2000) 1.19
Isolation of C. dubliniensis from insulin-using diabetes mellitus patients. J Oral Pathol Med (2000) 1.09
Candida dubliniensis at a cancer center. Clin Infect Dis (2001) 1.06
Initial case of Candida dubliniensis infection from Asia: non-mucosal infection. Med Mycol (2000) 0.97
Amino acid variations of cytochrome P-450 lanosterol 14 alpha-demethylase (CYP51A1) from fluconazoleresistant clinical isolates of Candida albicans. Rev Iberoam Micol (1999) 0.91
Identification of Candida dubliniensis in a study of HIV-seropositive pediatric dental patients. Pediatr Dent (2000) 0.86
Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. AIDS (1998) 0.85
Isolation of Candida dubliniensis from the oral cavity of an HIV-positive child in Brazil. Nihon Ishinkin Gakkai Zasshi (2000) 0.77
[Candida dubliniensis: 1st isolation in Argentina]. Rev Argent Microbiol (1998) 0.77
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science (2005) 4.74
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol (2002) 3.87
Candida biofilms: an update. Eukaryot Cell (2005) 3.58
Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother (2002) 3.18
Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother (2004) 2.96
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis (2004) 2.89
In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother (2002) 2.67
In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother (2002) 2.60
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett (2002) 2.50
Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note. J Clin Microbiol (2009) 2.44
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother (2008) 2.38
Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell (2006) 2.35
Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother (2002) 2.26
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet (2009) 2.15
Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2004) 2.11
Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production. Eukaryot Cell (2006) 1.92
Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med (2012) 1.90
UME6, a novel filament-specific regulator of Candida albicans hyphal extension and virulence. Mol Biol Cell (2008) 1.81
Expression levels of a filament-specific transcriptional regulator are sufficient to determine Candida albicans morphology and virulence. Proc Natl Acad Sci U S A (2008) 1.70
In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2002) 1.65
In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol (2002) 1.64
Disseminated Geosmithia argillacea infection in a German shepherd dog. Med Mycol (2009) 1.62
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis (2005) 1.56
Antifungal resistance in pathogenic fungi. Clin Infect Dis (2002) 1.52
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother (2008) 1.47
Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob Agents Chemother (2008) 1.47
Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother (2003) 1.47
Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. Med Mycol (2010) 1.45
Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother (2003) 1.45
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol (2012) 1.44
Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. Clin Infect Dis (2011) 1.39
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect (2006) 1.38
Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol (2003) 1.35
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis (2011) 1.34
Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother (2009) 1.31
Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer (2006) 1.30
Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol (2002) 1.30
Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis. J Clin Microbiol (2012) 1.30
Proteomics for the analysis of the Candida albicans biofilm lifestyle. Proteomics (2006) 1.27
Standardization of an experimental murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2006) 1.24
Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 1.22
Early treatment of candidemia in adults: a review. Med Mycol (2010) 1.21
Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Chemother (2013) 1.16
Bone morphogenetic protein 2 mediates dentin sialophosphoprotein expression and odontoblast differentiation via NF-Y signaling. J Biol Chem (2008) 1.16
Fungal disease of the nose and paranasal sinuses. J Allergy Clin Immunol (2011) 1.16
Invasive Aspergillus infections in hematologic malignancy patients. Semin Respir Infect (2002) 1.16
Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol (2009) 1.14
Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Microbiol (2002) 1.14
Overview of antifungal agents. Clin Chest Med (2009) 1.10
Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother (2011) 1.10
Isolation and characterization of the Cryptococcus neoformans MATa pheromone gene. Genetics (2002) 1.09
A seed and feed model for the formation of Candida albicans biofilms under flow conditions using an improved modified Robbins device. Rev Iberoam Micol (2008) 1.09
Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother (2008) 1.07
Aspergillus fumigatus stimulates leukocyte adhesion molecules and cytokine production by endothelial cells in vitro and during invasive pulmonary disease. Infect Immun (2008) 1.05
Biofilm formation by Candida albicans mutants for genes coding fungal proteins exhibiting the eight-cysteine-containing CFEM domain. FEMS Yeast Res (2006) 1.05
Identification and characterization of an Aspergillus fumigatus "supermater" pair. MBio (2011) 1.04
Molecular analysis of CPRalpha, a MATalpha-specific pheromone receptor gene of Cryptococcus neoformans. Eukaryot Cell (2002) 1.04
In vivo analysis of Aspergillus fumigatus developmental gene expression determined by real-time reverse transcription-PCR. Infect Immun (2008) 1.04
Comparison of lateral flow technology and galactomannan and (1->3)-beta-D-glucan assays for detection of invasive pulmonary aspergillosis. Clin Vaccine Immunol (2009) 1.02
Molecular genetic analyses of mating pheromones reveal intervariety mating or hybridization in Cryptococcus neoformans. Infect Immun (2002) 1.01